PFE
NYSE · Pharmaceuticals
Pfizer Inc.
$25.08
-0.13 (-0.52%)
Financial Highlights (FY 2026)
Revenue
62.43B
Net Income
7.75B
Gross Margin
75.8%
Profit Margin
12.4%
Rev Growth
-14.8%
D/E Ratio
0.75
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 75.8% | 75.8% | 67.2% | 67.2% |
| Operating Margin | 15.0% | 13.5% | 28.0% | 24.7% |
| Profit Margin | 12.4% | 11.8% | 22.4% | 21.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 62.43B | 73.28B | 23.86B | 20.26B |
| Gross Profit | 47.33B | 55.55B | 16.03B | 13.61B |
| Operating Income | 9.37B | 9.90B | 6.67B | 5.00B |
| Net Income | 7.75B | 8.19B | 5.34B | 4.44B |
| Gross Margin | 75.8% | 75.8% | 67.2% | 67.2% |
| Operating Margin | 15.0% | 13.5% | 28.0% | 24.7% |
| Profit Margin | 12.4% | 11.8% | 22.4% | 21.9% |
| Rev Growth | -14.8% | -14.8% | +12.0% | -6.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 30.77B | 30.77B | 56.00B | 68.28B |
| Total Equity | 41.07B | 41.07B | 73.99B | 77.95B |
| D/E Ratio | 0.75 | 0.75 | 0.76 | 0.88 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 14.23B | 15.87B | 9.52B | 7.04B |
| Free Cash Flow | — | — | 4.14B | 5.11B |